{"id":40775,"date":"2025-09-05T12:03:56","date_gmt":"2025-09-05T04:03:56","guid":{"rendered":"https:\/\/flcube.com\/?p=40775"},"modified":"2025-09-05T12:03:57","modified_gmt":"2025-09-05T04:03:57","slug":"hengrui-licenses-hrs%e2%80%911893-to-braveheart-bio-in-75-m-deal-global-myosin-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40775","title":{"rendered":"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced an exclusive licensing arrangement with <strong>Braveheart Bio<\/strong> of Delaware, USA, for its in\u2011house developed small\u2011molecule myosin inhibitor <strong>HRS\u20111893<\/strong>. The deal positions Hengrui as a strategic partner in the global cardiovascular drug market while granting Braveheart Bio worldwide rights (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Value<\/th><th>Notes<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td><strong>$65\u202fM<\/strong><\/td><td>$32.5\u202fM cash + $32.5\u202fM equity in Braveheart Bio<\/td><\/tr><tr><td><strong>Technology\u2011Transfer Milestone<\/strong><\/td><td><strong>$10\u202fM<\/strong><\/td><td>Paid upon successful transfer<\/td><\/tr><tr><td><strong>Total Immediate Cash<\/strong><\/td><td><strong>$75\u202fM<\/strong><\/td><td>Immediate return to Hengrui<\/td><\/tr><tr><td><strong>Future Milestones<\/strong><\/td><td>Up to <strong>$1.013\u202fB<\/strong><\/td><td>Clinical development &amp; sales milestones<\/td><\/tr><tr><td><strong>Royalty Structure<\/strong><\/td><td><strong>TBD<\/strong><\/td><td>Ongoing royalties on future sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hrs-1893-a-precision-myosin-inhibitor\">HRS\u20111893 \u2013 A Precision Myosin Inhibitor<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Selectively suppresses cardiac myosin ATPase activity, reducing excessive myocardial contraction.<\/li>\n\n\n\n<li><strong>Therapeutic Focus<\/strong> \u2013 Aims to mitigate left\u2011ventricular hypertrophy and improve diastolic relaxation in obstructive hypertrophic cardiomyopathy (oHCM).<\/li>\n\n\n\n<li><strong>Clinical Stage<\/strong> \u2013 <strong>Phase\u202fIII<\/strong> trials underway, poised for potential market entry.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Side<\/th><th>Reasoning<\/th><\/tr><\/thead><tbody><tr><td><strong>Hengrui<\/strong><\/td><td>Diversifies revenue with a high\u2011potential cardiovascular asset, retains China\u2011territory rights, and benefits from milestone\/royalty upside.<\/td><\/tr><tr><td><strong>Braveheart Bio<\/strong><\/td><td>Gains exclusive global rights to a late\u2011stage asset, supports its growth strategy in cardiovascular therapeutics, and secures a sizable equity stake in Hengrui.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-braveheart-bio-snapshot\">Braveheart Bio Snapshot<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded<\/strong> \u2013 2024, Delaware, USA<\/li>\n\n\n\n<li><strong>CEO<\/strong> \u2013 Travis Murdoch, 10+ years in life\u2011science investment, ops management, and clinical medicine<\/li>\n\n\n\n<li><strong>Backers<\/strong> \u2013 Forbion Capital, OrbiMed, and other institutional investors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiovascular Landscape<\/strong> \u2013 The myosin inhibitor class is gaining traction; HRS\u20111893\u2019s Phase\u202fIII data could reshape oHCM treatment paradigms.<\/li>\n\n\n\n<li><strong>Capital Efficiency<\/strong> \u2013 The upfront and milestone structure offers Hengrui immediate cash while preserving long\u2011term upside, a win\u2011win for both parties.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong> \u2013 By licensing outside China, Hengrui opens a new revenue channel while Braveheart Bio accelerates global commercialization.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced an exclusive licensing arrangement with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40776,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4336,69,2586,4228,852],"class_list":["post-40775","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-braveheart-bio","tag-cvd","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has granted U.S.\u2011based Braveheart Bio exclusive worldwide rights (outside China, HK, Macau, Taiwan) to develop, manufacture and commercialise its Phase\u202fIII myosin inhibitor HRS\u20111893. The agreement delivers an upfront $65\u202fM, a $10\u202fM milestone and up to $1.013\u202fB in future milestones and royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40775\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor\" \/>\n<meta property=\"og:description\" content=\"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has granted U.S.\u2011based Braveheart Bio exclusive worldwide rights (outside China, HK, Macau, Taiwan) to develop, manufacture and commercialise its Phase\u202fIII myosin inhibitor HRS\u20111893. The agreement delivers an upfront $65\u202fM, a $10\u202fM milestone and up to $1.013\u202fB in future milestones and royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40775\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-05T04:03:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-05T04:03:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor\",\"datePublished\":\"2025-09-05T04:03:56+00:00\",\"dateModified\":\"2025-09-05T04:03:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775\"},\"wordCount\":304,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0502.webp\",\"keywords\":[\"Braveheart Bio\",\"CVD\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40775#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40775\",\"name\":\"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0502.webp\",\"datePublished\":\"2025-09-05T04:03:56+00:00\",\"dateModified\":\"2025-09-05T04:03:57+00:00\",\"description\":\"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has granted U.S.\u2011based Braveheart Bio exclusive worldwide rights (outside China, HK, Macau, Taiwan) to develop, manufacture and commercialise its Phase\u202fIII myosin inhibitor HRS\u20111893. The agreement delivers an upfront $65\u202fM, a $10\u202fM milestone and up to $1.013\u202fB in future milestones and royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40775\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0502.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40775#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has granted U.S.\u2011based Braveheart Bio exclusive worldwide rights (outside China, HK, Macau, Taiwan) to develop, manufacture and commercialise its Phase\u202fIII myosin inhibitor HRS\u20111893. The agreement delivers an upfront $65\u202fM, a $10\u202fM milestone and up to $1.013\u202fB in future milestones and royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40775","og_locale":"en_US","og_type":"article","og_title":"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor","og_description":"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has granted U.S.\u2011based Braveheart Bio exclusive worldwide rights (outside China, HK, Macau, Taiwan) to develop, manufacture and commercialise its Phase\u202fIII myosin inhibitor HRS\u20111893. The agreement delivers an upfront $65\u202fM, a $10\u202fM milestone and up to $1.013\u202fB in future milestones and royalties.","og_url":"https:\/\/flcube.com\/?p=40775","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-05T04:03:56+00:00","article_modified_time":"2025-09-05T04:03:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40775#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40775"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor","datePublished":"2025-09-05T04:03:56+00:00","dateModified":"2025-09-05T04:03:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40775"},"wordCount":304,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40775#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0502.webp","keywords":["Braveheart Bio","CVD","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40775#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40775","url":"https:\/\/flcube.com\/?p=40775","name":"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40775#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40775#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0502.webp","datePublished":"2025-09-05T04:03:56+00:00","dateModified":"2025-09-05T04:03:57+00:00","description":"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) has granted U.S.\u2011based Braveheart Bio exclusive worldwide rights (outside China, HK, Macau, Taiwan) to develop, manufacture and commercialise its Phase\u202fIII myosin inhibitor HRS\u20111893. The agreement delivers an upfront $65\u202fM, a $10\u202fM milestone and up to $1.013\u202fB in future milestones and royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40775#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40775"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40775#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0502.webp","width":1080,"height":608,"caption":"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40775#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Licenses HRS\u20111893 to Braveheart Bio in $75\u202fM Deal \u2013 Global Myosin Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40775"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40775\/revisions"}],"predecessor-version":[{"id":40777,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40775\/revisions\/40777"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40776"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}